MAP2K7 and neoplasm: Finally, treatment with a MEK inhibitor promotes antitumor immunity by modulating the expression of programmed death-ligand 1 (PD-L1),45 which might contribute to the increased efficacy of 5-ALA-PDT combined with the MEK inhibitor in an immunocompetent tumour model.